RET and cancer: In a large study involving multiple advanced cancers types, using a hybrid-capture targeted 70-gene cfDNA test, KIF5B-RET fusion was dominant in NSCLC, and that non-KIF5B-RET fusion contributed to anti-EGFR resistance, highlighting the importance of knowing the specific gene partner [101].